TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33650444

Group type: EXPERIMENTAL
Intervention: Social interaction with a therapy dog (no physical interaction)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Social plus physical interaction with a therapy dog
Number of subjects: 75

Group type: COMPARATOR
Intervention: No interaction with a therapy dog (control)
Number of subjects: 75
Study: 32463593

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate ODT (50 mg) without water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate ODT (50 mg) with water
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional sildenafil citrate tablets (50 mg) with water
Number of subjects: 36
Study: 35395638

Group type: EXPERIMENTAL
Intervention: Bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33373763

Group type: EXPERIMENTAL
Intervention: Warfarin therapy to achieve a target INR of 1.5–2
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 86
Study: 32755488

Group type: EXPERIMENTAL
Intervention: Oxycodone included with multimodal pain medications (group 1)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Optional prescription for oxycodone (group 2)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 95
Study: 34762211

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 25
Study: 34488843

Group type: COMPARATOR
Intervention: Status quo framing (1500 respondents)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Qualitative risk labels (e.g. 'very low risk')
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Comparison to COVID-19 mortality
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Comparison to motor vehicle mortality
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Absolute vs relative risk presentation
Number of subjects: 12000
Study: 33788454

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (20 minutes each session, once every other day for 8 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Medication group (Nimodipine 30 mg once a day for 8 weeks)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 210
Study: 35970829

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 130

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 130

Group type: COMPARATOR
Intervention: Combination of exercise and liraglutide
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 130
Study: 34491645

Group type: EXPERIMENTAL
Intervention: Acupuncture (at Neiguan (PC 6), Hegu (LI 4), Yintang (GV 29), and Baihui (GV 20), twice a day until mechanical ventilation was offline)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Routine nursing and treatment of severe pneumonia (Control group)
Number of subjects: 188
Study: 32353805

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Neostigmine (50 μg/kg) with 8 μg/kg glycopyrrolate
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 92

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 92
Study: 36274079

Group type: EXPERIMENTAL
Intervention: Far-infrared emitting fabric (FIR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32910179

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 200
Study: 32027446

Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) with 240 mL of 0% alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) with 240 mL of 40% alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone twice-daily (OTD) with 240 mL of 40% alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxycodone twice-daily (OTD) with 240 mL of 0% alcohol
Number of subjects: 20
Study: 35923485

Group type: EXPERIMENTAL
Intervention: Videos of 'people like me' (patient stories)
Number of subjects: 14
Study: 34177615

Group type: EXPERIMENTAL
Intervention: Active laser PBM (100 mW output power, irradiance of 35.7 W cm–2, total energy of 28 J/arm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo laser PBM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Active laser PBM and Placebo
Number of subjects: 13
Study: 35121204

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33829742

Group type: COMPARATOR
Intervention: 3-minute balloon inflation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 5-minute balloon inflation
Number of subjects: 61
Study: 35065898

Group type: EXPERIMENTAL
Intervention: Nurses consulting patients and providing follow-up care in diabetes management in 2016
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nurses completing Diabetes Annual Reviews independently of doctors in 2016
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Access to educational resources by nurses in 2016
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Support felt by nurses for participating in diabetes reviews in 2016
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nurses addressing cardiovascular risk factors during reviews in 2016
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nurses reporting participation in diabetes reviews conducted by designated nurses in 2016
Number of subjects: 26
Study: 33517855

Group type: EXPERIMENTAL
Intervention: Prehypertensive and hypertensive group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overweight/obese BMI group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: BMI and BP
Number of subjects: 171
Study: 36691187

Group type: EXPERIMENTAL
Intervention: Certain communication about COVID-19 vaccine effectiveness
Number of subjects: 328

Group type: COMPARATOR
Intervention: Uncertain communication about COVID-19 vaccine effectiveness
Number of subjects: 328
Study: 32202658

Group type: EXPERIMENTAL
Intervention: QEWP-C-5
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: LOC-ED-Q
Number of subjects: 218

Group type: COMPARATOR
Intervention: EDE
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: LOC-eating presence
Number of subjects: 218
Study: 34519709

Group type: EXPERIMENTAL
Intervention: Muscle flap reconstruction
Number of subjects: 145
Study: 33179380

Group type: EXPERIMENTAL
Intervention: Overall obesity (measured by Body Mass Index - BMI)
Number of subjects: 74317

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (measured by Waist Circumference - WC)
Number of subjects: 74317

Group type: EXPERIMENTAL
Intervention: Overall obesity (BMI)
Number of subjects: 74317

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC)
Number of subjects: 74317
Study: 36411989

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein diet (LC/HP, 30% energy from protein, 40% energy from carbohydrate)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein diet (LC/HP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 25
Study: 32894088

Group type: EXPERIMENTAL
Intervention: mirtazapine-placebo
Number of subjects: 258

Group type: COMPARATOR
Intervention: amitriptyline-placebo
Number of subjects: 258

Group type: COMPARATOR
Intervention: trazodone-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: citalopram-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: desvenlafaxine-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: duloxetine-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: escitalopram-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: fluoxetine-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: sertraline-placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: venlafaxine-placebo
Number of subjects: 258
Study: 36261056

Group type: EXPERIMENTAL
Intervention: Strength training of the nonhemiplegic side (NHS)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual rehabilitation training (control group)
Number of subjects: 139
Study: 33640289

Group type: EXPERIMENTAL
Intervention: 20 mL mentholated popsicle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (absolute fasting)
Number of subjects: 50
Study: 32998416

Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Individualized Dietary Prescription
Number of subjects: 88
Study: 36327327

Group type: EXPERIMENTAL
Intervention: Information provision messages about recycling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32160096

Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 145
Study: 34214153

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 or 30 μg daily)
Number of subjects: 525
Study: 32434376

Group type: EXPERIMENTAL
Intervention: Auricular therapy (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham procedure (Group B)
Number of subjects: 50
Study: 36169160

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clobetasol lotion 0.05% once at night
Number of subjects: 40
Study: 33370050

Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen (NSAID)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 5 mg hydrocodone with 325 mg acetaminophen (opioid)
Number of subjects: 70
Study: 33941951

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 164

Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 164
Study: 32059704

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Gemcitabine + Cisplatin (3 cycles pre- and post-surgery)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Surgery alone followed by therapy of investigator's choice
Number of subjects: 333
Study: 34739947

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 151
Study: 35056349

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electroacupuncture at left PC5, PC6, ST36, and ST37, once weekly for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham acupuncture treatment (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 44
Study: 35413570

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (30 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33036591

Group type: EXPERIMENTAL
Intervention: SHAPE group intervention (10-week course delivered as group sessions)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 372
Study: 36498457

Group type: EXPERIMENTAL
Intervention: Ramosetron (5 μg; n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 70
Study: 32008289

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neostigmine (2 mg) combined with atropine (0.5-1.0 mg)
Number of subjects: 100
Study: 35268040

Group type: EXPERIMENTAL
Intervention: IGOBE program (healthy lifestyle habits program in six weekly sessions)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: IGOBE program
Number of subjects: 456
Study: 34860129

Group type: EXPERIMENTAL
Intervention: Memory exergame training (IG: n=29)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG: n=21)
Number of subjects: 50
Study: 37415125

Group type: EXPERIMENTAL
Intervention: Gradient Boosting Decision Tree (GBDT)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Decision Tree (DT)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Machine Learning Classifiers (GBDT and LR)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Long diameter (CT feature)
Number of subjects: 231
Study: 32930011

Group type: EXPERIMENTAL
Intervention: Culturally adapted Family Intervention (CulFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 0
Study: 36167891

Group type: EXPERIMENTAL
Intervention: Therapeutic dispersible zinc tablets (TZ)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient powder (MNP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Daily preventive zinc tablets (PZ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo powder (control)
Number of subjects: 200
Study: 34101714

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 μg kg‐1 h‐1) combined with GDHT
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline combined with GDHT
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study: 33290900

Group type: EXPERIMENTAL
Intervention: High clonogenic potential (CP) STBSs cultures
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low clonogenic potential (CP) STBSs cultures
Number of subjects: 54
Study: 32340838

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy and Dry Needling (ESWT-DN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 40
Study: 34510243

Group type: EXPERIMENTAL
Intervention: CSC‐C (Continuous Single Culture Complete)
Number of subjects: 226

Group type: COMPARATOR
Intervention: G5 series (Vitrolife)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: CSC‐C
Number of subjects: 226

Group type: COMPARATOR
Intervention: G5 series
Number of subjects: 226
Study: 33309486

Group type: EXPERIMENTAL
Intervention: SMS-based surveillance after immunisation
Number of subjects: 6555
Study: 35648095

Group type: EXPERIMENTAL
Intervention: Bloodletting (phlebotomy)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phlebotomy procedures
Number of subjects: 14
Study: 34318597

Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nezulcitinib (1, 3, or 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 32215577

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation (SABR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 54
Study: 34422085

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT), two times/week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual Lymphatic Drainage (MLD), two times/week for 4 weeks
Number of subjects: 30
Study: 34921022

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 430

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 430
Study: 35577898

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention with a reduced calorie diet (1200–1800 kcal/d) and increased physical activity (300 min/wk)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lower sleep efficiency, higher wake after sleep onset (WASO), more awakenings, and higher sleep onset latency (SOL)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lower sleep efficiency, more awakenings, and higher SOL
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Later waketime, longer time in bed, longer sleep duration, higher WASO, more awakenings, and higher SOL
Number of subjects: 156
Study: 33513820

Group type: EXPERIMENTAL
Intervention: Proxian® (probiotic supplement) for 60 days
Number of subjects: 32
Study: 33323210

Group type: EXPERIMENTAL
Intervention: SMART-CR/SP (smartphone-based cardiac rehabilitation via WeChat)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (standard outpatient cardiology follow-up without formal cardiac rehabilitation)
Number of subjects: 312
Study: 36306974

Group type: EXPERIMENTAL
Intervention: CureSight treatment (90 minutes/day, 5 days/week for 16 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Patching (2 hours/day, 7 days/week for 16 weeks)
Number of subjects: 103
Study: 33506629

Group type: COMPARATOR
Intervention: Single Pass (SP) emission
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MultiPass emission (MoveoPL)
Number of subjects: 63
Study: 33272279

Group type: EXPERIMENTAL
Intervention: mHealth solution using the 24alife app with a compliance rate of 94.1%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: mHealth solution using the 24alife app
Number of subjects: 17
Study: 35440229

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure preceded by a brief food exposure (IE + Food)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Assessment Control
Number of subjects: 47
Study: 33169186

Group type: EXPERIMENTAL
Intervention: HLX02
Number of subjects: 109

Group type: COMPARATOR
Intervention: CN-trastuzumab
Number of subjects: 109

Group type: COMPARATOR
Intervention: EU-trastuzumab
Number of subjects: 109
Study: 34923514

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES), 30 minutes/week for 6 months
Number of subjects: 15
Study: 33627641

Group type: EXPERIMENTAL
Intervention: Ensembled deep learning model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human experts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis based on smartphone photos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis based on video sequences by the model
Number of subjects: 0
Study: 32483634

Group type: EXPERIMENTAL
Intervention: PREP-C assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 36431167

Group type: EXPERIMENTAL
Intervention: Topical intervention (SuperCalm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention (InnerCalm and SuperCalm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral intervention (InnerCalm)
Number of subjects: 0
Study: 32620260

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia without tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: General anaesthesia without tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: General anaesthesia with tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Without tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: With tourniquet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Tourniquet use
Number of subjects: 413
Study: 32024950

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously on intense dosing schedule
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously on intermediate dosing schedule
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously on short dosing schedule
Number of subjects: 123
Study: 33146774

Group type: EXPERIMENTAL
Intervention: Strip meniscometry
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Schirmer's 1 test
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Jones test
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: OCT meniscometry
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Number of subjects: 201
Study: 33257632

Group type: EXPERIMENTAL
Intervention: FDC treatment in Shandong Province for six months
Number of subjects: 2353

Group type: EXPERIMENTAL
Intervention: FDC treatment in Jilin Province for six months
Number of subjects: 2353

Group type: COMPARATOR
Intervention: Comparison of both regimens
Number of subjects: 2353
Study: 36445907

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dry Needling (DN)
Number of subjects: 30
Study: 32492186

Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel node navigation surgery (LSNNS)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Laparoscopic standard gastrectomy (LSG)
Number of subjects: 580
Study: 35086508

Group type: EXPERIMENTAL
Intervention: Complex intervention including community health worker education, distribution of birth kits with misoprostol, and transport subsidy.
Number of subjects: 9565

Group type: COMPARATOR
Intervention: Control group (pre-intervention period).
Number of subjects: 9565

Group type: EXPERIMENTAL
Intervention: Secondary outcomes related to antenatal and postpartum care and postpartum hemorrhage.
Number of subjects: 9565
Study: 33518615

Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Post-meal faster aspart
Number of subjects: 66

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 66
Study: 36474739

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) alone with 4 mg/kg plain lidocaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lidocaine-prilocaine cream (LPC) applied to the phallus 1 hour before DPNB
Number of subjects: 72
Study: 33461398

Group type: EXPERIMENTAL
Intervention: Virtual monitoring clinic (VMC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study: 33908687

Group type: EXPERIMENTAL
Intervention: Cotadutide 100 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cotadutide 200 μg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cotadutide 300 μg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93